Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
steroids for topical use, acetal derivatives	1204	67-73-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: fluocinolone acetonide fluocinolonacetonid fluocinolone acetonide dihydrate fluocinolone acetonide oil	A glucocorticoid derivative used topically in the treatment of various skin disorders. It is usually employed as a cream, gel, lotion, or ointment. It has also been used topically in the treatment of inflammatory eye, ear, and nose disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732) Molecular weight: 452.50 Formula: C24H30F2O6 CLOGP: 2.25 LIPINSKI: 0 HAC: 6 HDO: 2 TPSA: 93.06 ALOGS: -3.92 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

fluocinolone acetonide
fluocinolonacetonid
fluocinolone acetonide dihydrate
fluocinolone acetonide oil

A glucocorticoid derivative used topically in the treatment of various skin disorders. It is usually employed as a cream, gel, lotion, or ointment. It has also been used topically in the treatment of inflammatory eye, ear, and nose disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732)

Molecular weight: 452.50
Formula: C24H30F2O6
CLOGP: 2.25
LIPINSKI: 0
HAC: 6
HDO: 2
TPSA: 93.06
ALOGS: -3.92
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	5 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	1.975		Moderate	0.69
caco2-efflux	Caco-2 efflux ratio (BA/AB)	2.761		Moderate	0.69
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	42.170	10^-6 cm/s	Moderate	0.69
dh-clint	Dog hepatocyte intrinsic clearance	6.792	uL/min/10^6 cells	Moderate	0.69
dppb	Dog plasma protein binding (% unbound)	27.360	%	Moderate	0.69
fcs-ppb	Fetal calf serum protein binding (% unbound)	35.150	%	Moderate	0.69
herg	hERG pIC50	4.393	pIC50	Moderate	0.69
hh-clint	Human hepatocyte intrinsic clearance	3.622	uL/min/10^6 cells	Moderate	0.69
hlm-clint	Human liver microsomal intrinsic clearance	12.735	uL/min/mg protein	Moderate	0.69
hppb	Human plasma protein binding (% unbound)	23.940	%	Moderate	0.69
kinase-safety-class	ACVR2B,CAMK2D,CDK5,EIF2AK3,GRK2,ITK,MAPK10,PDK1,PDK2,PDK4,PRKDC	11
kinase-selectivity-class	GRK2	1
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	6.668		Moderate	0.69
mh-clint	Mouse hepatocyte intrinsic clearance	15.776		Moderate	0.69
mppb	Mouse plasma protein binding (% unbound)	28.520		Moderate	0.69
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	13.002		Moderate	0.69
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	32.570	%	Moderate	0.69
rh-clint	Rat hepatocyte intrinsic clearance	20.184	uL/min/10^6 cells	Moderate	0.69
rh-fuinc	Rat hepatocyte fraction unbound in incubation	73.540	%	Moderate	0.69
rppb	Rat plasma protein binding (% unbound)	20.340	%	Moderate	0.69
solubility-dd	Solubility at pH 7.4 in DMSO	616.595	uM	Moderate	0.69

Approvals:

Date	Agency	Company	Orphan
Feb. 15, 1963	FDA	MEDIMETRIKS PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Off label use	275.45	25.10	271	3310	1101981	89522885
Intraocular pressure increased	189.20	25.10	46	3535	7047	90617819
Circumstance or information capable of leading to medication error	162.50	25.10	38	3543	4929	90619937
Device failure	160.05	25.10	40	3541	6857	90618009
Medical device removal	123.06	25.10	24	3557	1309	90623557
Device dislocation	117.99	25.10	45	3536	31437	90593429
Drug delivery system issue	117.40	25.10	17	3564	142	90624724
Dermatitis atopic	115.50	25.10	41	3540	23431	90601435
Product dose omission issue	111.55	25.10	92	3489	291595	90333271
Hypotony of eye	111.28	25.10	17	3564	211	90624655
Psoriasis	90.77	25.10	62	3519	147692	90477174
Vitrectomy	88.08	25.10	14	3567	228	90624638
Corneal oedema	86.26	25.10	19	3562	1882	90622984
No adverse event	79.16	25.10	43	3538	67939	90556927
Needle issue	71.03	25.10	25	3556	13909	90610957
Implantation complication	62.29	25.10	8	3573	23	90624843
Pruritus	51.45	25.10	83	3498	541442	90083424
Product administration error	49.24	25.10	23	3558	26400	90598466
Vitreous haemorrhage	45.13	25.10	12	3569	2614	90622252
Ocular lymphoma	43.43	25.10	7	3574	125	90624741
Skin exfoliation	42.81	25.10	29	3552	67884	90556982
Dry skin	38.20	25.10	30	3551	88043	90536823
Drug delivery system malfunction	37.02	25.10	9	3572	1372	90623494
Eczema	36.75	25.10	24	3557	52846	90572020
Trabeculectomy	35.83	25.10	5	3576	31	90624835
Endophthalmitis	34.13	25.10	11	3570	4674	90620192
Skin discolouration	32.97	25.10	21	3560	44294	90580572
Skin plaque	32.86	25.10	13	3568	9962	90614904
Device dispensing error	27.49	25.10	5	3576	186	90624680
Glaucoma drainage device placement	27.42	25.10	3	3578	0	90624866
Drug dose omission by device	25.76	25.10	11	3570	10220	90614646
Sleep disorder due to a general medical condition	25.58	25.10	18	3563	44720	90580146
Patient uncooperative	25.51	25.10	5	3576	279	90624587
Corneal decompensation	25.41	25.10	4	3577	61	90624805

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Intraocular pressure increased	245.85	39.58	57	1841	6376	42613061
Device failure	227.51	39.58	46	1852	2697	42616740
Off label use	222.67	39.58	198	1700	638137	41981300
Circumstance or information capable of leading to medication error	219.23	39.58	44	1854	2484	42616953
Medical device removal	178.33	39.58	25	1873	141	42619296
Device dislocation	108.71	39.58	31	1867	7800	42611637
Drug delivery system issue	101.24	39.58	14	1884	70	42619367
No adverse event	97.16	39.58	43	1855	38978	42580459
Trabeculectomy	87.16	39.58	11	1887	22	42619415
Cataract operation	72.37	39.58	16	1882	1431	42618006
Glaucoma drainage device placement	72.17	39.58	8	1890	0	42619437
Dermatitis atopic	71.02	39.58	25	1873	12379	42607058
Vitrectomy	70.58	39.58	11	1887	138	42619299
Corneal oedema	65.87	39.58	15	1883	1533	42617904
Glaucoma	64.45	39.58	21	1877	8227	42611210
Needle issue	63.28	39.58	21	1877	8706	42610731
Macular oedema	53.43	39.58	15	1883	3554	42615883
Product dose omission issue	50.66	39.58	47	1851	154318	42465119
Trabeculoplasty	50.49	39.58	6	1892	5	42619432
Ocular hypertension	48.24	39.58	11	1887	1130	42618307
Implantation complication	45.81	39.58	6	1892	18	42619419
Hypotony of eye	44.36	39.58	8	1890	251	42619186

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Device failure	400.99	27.20	83	3707	7124	110578385
Circumstance or information capable of leading to medication error	396.85	27.20	78	3712	5155	110580354
Intraocular pressure increased	313.32	27.20	73	3717	10803	110574706
Medical device removal	266.25	27.20	42	3748	759	110584750
Drug delivery system issue	181.44	27.20	26	3764	235	110585274
Dermatitis atopic	153.46	27.20	50	3740	25491	110560018
Vitrectomy	148.61	27.20	22	3768	254	110585255
Device dislocation	146.71	27.20	51	3739	31653	110553856
No adverse event	142.54	27.20	63	3727	73776	110511733
Product dose omission issue	123.73	27.20	96	3694	321686	110263823
Needle issue	119.72	27.20	38	3752	17802	110567707
Hypotony of eye	108.21	27.20	18	3772	457	110585052
Corneal oedema	105.71	27.20	24	3766	3149	110582360
Trabeculectomy	99.56	27.20	13	3777	53	110585456
Glaucoma	80.70	27.20	30	3760	22487	110563022
Drug delivery system malfunction	75.77	27.20	15	3775	1020	110584489
Product administration error	75.76	27.20	33	3757	37184	110548325
Glaucoma drainage device placement	74.26	27.20	8	3782	0	110585509
Visual acuity reduced	60.54	27.20	27	3763	32146	110553363
Drug dose omission by device	58.15	27.20	21	3769	14495	110571014
Off label use	55.83	27.20	143	3647	1500042	109085467
Trabeculoplasty	55.69	27.20	6	3784	0	110585509
Cataract operation	54.22	27.20	16	3774	5867	110579642
Psoriasis	51.93	27.20	41	3749	139952	110445557
Macular oedema	51.55	27.20	16	3774	6950	110578559
Vitreous haemorrhage	48.93	27.20	14	3776	4606	110580903
Pruritus	48.81	27.20	78	3712	581482	110004027
Ocular hypertension	47.86	27.20	12	3778	2396	110583113
Retinal degeneration	46.94	27.20	11	3779	1655	110583854
Ciliary body operation	46.41	27.20	5	3785	0	110585509
Implantation complication	45.47	27.20	6	3784	27	110585482
Dry skin	45.32	27.20	34	3756	107619	110477890
Device dispensing error	40.57	27.20	7	3783	222	110585287
Sleep disorder due to a general medical condition	37.62	27.20	23	3767	52089	110533420
Endophthalmitis	37.17	27.20	13	3777	8174	110577335
Device difficult to use	36.07	27.20	16	3774	18789	110566720
Patient uncooperative	35.99	27.20	8	3782	952	110584557
Ocular lymphoma	34.17	27.20	6	3784	211	110585298
Eczema	33.04	27.20	24	3766	72269	110513240
Cystoid macular oedema	31.98	27.20	9	3781	2791	110582718
Corneal decompensation	31.96	27.20	5	3785	85	110585424
Eye pain	30.87	27.20	20	3770	50079	110535430

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C05AA10	CARDIOVASCULAR SYSTEM VASOPROTECTIVES AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Corticosteroids
ATC	D07AC04	DERMATOLOGICALS CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS CORTICOSTEROIDS, PLAIN Corticosteroids, potent (group III)
ATC	D07BC02	DERMATOLOGICALS CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS Corticosteroids, potent, combinations with antiseptics
ATC	D07CC02	DERMATOLOGICALS CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS Corticosteroids, potent, combinations with antibiotics
ATC	S01BA15	SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFLAMMATORY AGENTS Corticosteroids, plain
ATC	S01CA10	SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION Corticosteroids and antiinfectives in combination
ATC	S02BA08	SENSORY ORGANS OTOLOGICALS CORTICOSTEROIDS Corticosteroids
ATC	S02CA05	SENSORY ORGANS OTOLOGICALS CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION Corticosteroids and antiinfectives in combination
FDA MoA	N0000175450	Corticosteroid Hormone Receptor Agonists
FDA EPC	N0000175576	Corticosteroid
MeSH PA	D000893	Anti-Inflammatory Agents
MeSH PA	D005938	Glucocorticoids
MeSH PA	D006728	Hormones
CHEBI has role	CHEBI:35441	antiinfective agent
CHEBI has role	CHEBI:35472	anti-inflammatory drug
CHEBI has role	CHEBI:39456	antiglaucoma drug
CHEBI has role	CHEBI:50177	dermatologic drug
CHEBI has role	CHEBI:50748	antipsoriatic
CHEBI has role	CHEBI:59683	antipruritic drug
CHEBI has role	CHEBI:66981	ophthalmology drug
CHEBI has role	CHEBI:67079	anti-inflammatory agent

Related Drugs by ATC class:

C05AA Corticosteroids 8 drugs

betamethasone dexamethasone fluocinonide fluocortolone fluorometholone hydrocortisone prednisolone triamcinolone

D07AC Corticosteroids, potent (group III) 20 drugs

amcinonide beclometasone dipropionate betamethasone budesonide desoximetasone diflorasone diacetate diflucortolone difluprednate fluclorolone fludroxycortide fluocinonide fluocortolone show all 20 →

D07BC Corticosteroids, potent, combinations with antiseptics 3 drugs

betamethasone diflucortolone fluocortolone

D07CC Corticosteroids, potent, combinations with antibiotics 5 drugs

beclometasone dipropionate betamethasone fludroxycortide fluocinonide fluocortolone

S01BA Corticosteroids, plain 15 drugs

alclometasone dipropionate betamethasone clobetasol propionate clobetasone butyrate desonide dexamethasone difluprednate fluorometholone formocortal hydrocortisone loteprednol etabonate medrysone show all 15 →

S01CA Corticosteroids and antiinfectives in combination 11 drugs

betamethasone chloroprednisone clobetasone butyrate dexamethasone fludrocortisone acetate fluocortolone fluorometholone hydrocortisone loteprednol etabonate methylprednisolone prednisolone

S02BA Corticosteroids 4 drugs

betamethasone dexamethasone hydrocortisone prednisolone

S02CA Corticosteroids and antiinfectives in combination 6 drugs

dexamethasone fludrocortisone acetate flumetasone hydrocortisone prednisolone triamcinolone

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Choroiditis	indication	16553002	DOID:11406
Atopic dermatitis	indication	24079001	DOID:3310
Chloasma	indication	36209000
Contact dermatitis	indication	40275004	DOID:2773
Seborrheic dermatitis	indication	50563003	DOID:8741
Lichen simplex chronicus	indication	53891004
Granuloma annulare	indication	65508009	DOID:3777
Pruritus ani	indication	90446007
Pityriasis simplex	indication	200767005
Discoid lupus erythematosus	indication	200938002
Plaque psoriasis	indication	200965009
Scalp psoriasis	indication	238608008
Pruritus of genital organs	indication	267802000
Eruption of skin	indication	271807003	DOID:0050486
Primary cutaneous T-cell lymphoma	indication	400122007
Otitis Externa Eczema	indication
Herpes simplex keratitis	contraindication	9389005
Herpes zoster auricularis	contraindication	21954000	DOID:9210
Sunburn	contraindication	23346002
Glaucoma	contraindication	23986001	DOID:1686
Fungal infection of eye	contraindication	31194008
Herpes zoster keratoconjunctivitis	contraindication	42448002
Eczema	contraindication	43116000
Tuberculosis of eye	contraindication	49107007
Herpes simplex keratoconjunctivitis	contraindication	72321008
Third degree burn injury	contraindication	80247002
Herpes simplex	contraindication	88594005	DOID:8566
Open wound	contraindication	125643001
Tuberculosis of ear	contraindication	186269001
Telangiectasia disorder	contraindication	247479008
Pregnancy, function	contraindication	289908002
Viral ear infection	contraindication	312137007
Fungal ear infection	contraindication	312148000
Fungal keratitis	contraindication	314558005
Adrenal cortical hypofunction	contraindication	386584007	DOID:10493
Vaccinia keratitis	contraindication	397552005
Herpes zoster keratitis	contraindication	397573005
Atrophoderma	contraindication	399979006
Peripheral vascular disease	contraindication	400047006
Breastfeeding (mother)	contraindication	413712001
Denuded skin	contraindication	418242004

🐶 Veterinary Drug Use

Species	Use	Relation
Cats	Pruritus and inflammation associated with acute otitis externa	Indication
Cats	Pruritus and inflammation associated with acute and chronic dermatoses	Indication
Dogs	Pruritus and inflammation associated with superficial acute and chronic dermatoses	Indication
Dogs	Allergic and acute moist dermatoses	Indication
Dogs	Nonspecific dermatoses	Indication
Dogs	Wound infections	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Neo-synalar Cream	Bausch Health US LLC	2
Synalar Cream Veterinary	Bausch Health US LLC	1
Synalar Solution Veterinary	Bausch Health US LLC	1
Synotic Otic Solution	Zoetis Inc.	2
Synsac Solution	Zoetis Inc.	2

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.08	acidic
pKa2	11.78	acidic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
0.18MG	YUTIQ	ALIMERA SCIENCES INC	N210331	Oct. 12, 2018	RX	IMPLANT	INTRAVITREAL	7998108	Jan. 12, 2028	A METHOD OF INJECTING AN IMPLANT
0.19MG	ILUVIEN	ALIMERA SCIENCES INC	N201923	Sept. 26, 2014	RX	IMPLANT	INTRAVITREAL	9849027	Nov. 7, 2028	THE TREATMENT OF DIABETIC MACULAR EDEMA (DME) IN PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH A COURSE OF CORTICOSTEROIDS AND DID HAVE A CLINICALLY SIGNIFICANT RISE IN INTRAOCULAR PRESSURE
0.19MG	ILUVIEN	ALIMERA SCIENCES INC	N201923	Sept. 26, 2014	RX	IMPLANT	INTRAVITREAL	9849027	Nov. 7, 2028	TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
EQ 0.3% BASE;0.025%	OTOVEL	LAB SALVAT	N208251	April 29, 2016	RX	SOLUTION/DROPS	OTIC	8932610	March 24, 2030	TREATMENT OF ACUTE OTITIS MEDIA

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Glucocorticoid receptor	Nuclear hormone receptor	P04150	GCR_HUMAN	AGONIST	Ki	8.85		DRUG MATRIX	CHEMBL
Progesterone receptor	Transcription factor		Q690N0_BOVIN		Ki	8.48		DRUG MATRIX

External reference:

ID	Source
4018222	VUID
N0000146554	NUI
D01825	KEGG_DRUG
4018222	VANDF
4019759	VANDF
C0016298	UMLSCUI
CHEBI:31623	CHEBI
CHEMBL989	ChEMBL_ID
D005446	MESH_DESCRIPTOR_UI
DB00591	DRUGBANK_ID
7077	IUPHAR_LIGAND_ID
1046	INN_ID
0CD5FD6S2M	UNII
6215	PUBCHEM_CID
DB12553	DRUGBANK_ID
25126	RXNORM
4738	MMSL
002193	NDDF
011117	NDDF
28426008	SNOMEDCT_US
395977002	SNOMEDCT_US
396059004	SNOMEDCT_US
C0060507	UMLSCUI
CHEMBL1201390	ChEMBL_ID
807-38-5	SECONDARY_CAS_RN
91488	PUBCHEM_CID
C035394	MESH_SUPPLEMENTAL_RECORD_UI
CT1IX58L9S	UNII
CHEBI:5108	CHEBI
0CD5FD6S2M	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Fluocinolone Acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	0168-0059	SOLUTION	0.10 mg	TOPICAL	ANDA	18 sections
Fluocinolone Acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	0168-0064	OINTMENT	0.25 mg	TOPICAL	ANDA	18 sections
TRI-LUMA	HUMAN PRESCRIPTION DRUG LABEL	3	0299-5950	CREAM	0.10 mg	TOPICAL	NDA	24 sections
Fluocinolone Acetonide Topical	HUMAN PRESCRIPTION DRUG LABEL	1	0591-2990	SOLUTION	0.10 mg	TOPICAL	ANDA	17 sections
Fluocinolone Acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0222	CREAM	0.25 mg	TOPICAL	ANDA	10 sections
Fluocinolone Acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0223	CREAM	0.10 mg	TOPICAL	ANDA	10 sections
Fluocinolone Acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0224	OINTMENT	0.25 mg	TOPICAL	ANDA	10 sections
FLUOCINOLONE ACETONIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0709	CREAM	0.25 mg	TOPICAL	ANDA	11 sections
fluocinolone acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	10135-670	SOLUTION	0.10 mg	TOPICAL	ANDA	18 sections
Fluocinolone Acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	16590-097	CREAM	0.10 mg	TOPICAL	ANDA	11 sections
Fluocinolone Acetonide Topical Solution USP, 0.01%	HUMAN PRESCRIPTION DRUG LABEL	1	21922-003	SOLUTION	0.10 mg	TOPICAL	ANDA	17 sections
Retisert	HUMAN PRESCRIPTION DRUG LABEL	1	24208-416	IMPLANT	0.59 mg	INTRAVITREAL	NDA	22 sections
OTOVEL	HUMAN PRESCRIPTION DRUG LABEL	2	24338-080	SOLUTION	0.06 mg	AURICULAR (OTIC)	NDA	26 sections
Flac Otic Oil	HUMAN PRESCRIPTION DRUG LABEL	1	39328-079	OIL	0.11 mg	AURICULAR (OTIC)	ANDA	22 sections
Ciprofloxacin and Fluocinolone Acetonide	HUMAN PRESCRIPTION DRUG LABEL	2	42195-128	SOLUTION	0.06 mg	AURICULAR (OTIC)	NDA authorized generic	26 sections
Fluocinolone Acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	43386-069	SOLUTION	0.10 mg	TOPICAL	ANDA	15 sections
Synalar	HUMAN PRESCRIPTION DRUG LABEL	1	43538-900	CREAM	0.25 mg	TOPICAL	NDA	21 sections
Synalar	HUMAN PRESCRIPTION DRUG LABEL	1	43538-910	OINTMENT	0.25 mg	TOPICAL	NDA	19 sections
Neo-Synalar	HUMAN PRESCRIPTION DRUG LABEL	2	43538-940	CREAM	0.25 mg	TOPICAL	ANDA	20 sections
Fluocinolone Acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	45802-009	OIL	0.11 mg	AURICULAR (OTIC)	ANDA	22 sections
Fluocinolone acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	45802-485	OIL	0.01 mg	TOPICAL	ANDA	22 sections
fluocinolone acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	45802-887	OIL	0.01 mg	TOPICAL	ANDA	21 sections
Fluocinolone AcetonideOil	HUMAN PRESCRIPTION DRUG LABEL	1	50090-6780	OIL	0.11 mg	TOPICAL	ANDA	20 sections
Fluocinolone acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	50090-7958	OIL	0.01 mg	TOPICAL	ANDA	22 sections
Fluocinolone Acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	51672-1356	OIL	0.11 mg	TOPICAL	ANDA	25 sections
Fluocinolone Acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	51672-1357	OIL	0.11 mg	TOPICAL	ANDA	21 sections
Fluocinolone Acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	51672-1365	SOLUTION	0.10 mg	TOPICAL	ANDA	20 sections
Fluocinolone Acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	52565-012	SOLUTION	0.10 mg	TOPICAL	NDA AUTHORIZED GENERIC	20 sections
Fluocinolone Acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	52565-013	OINTMENT	0.25 mg	TOPICAL	NDA AUTHORIZED GENERIC	20 sections
Fluocinolone Acetonide	HUMAN PRESCRIPTION DRUG LABEL	1	52565-020	CREAM	0.25 mg	TOPICAL	NDA AUTHORIZED GENERIC	20 sections

Ask DrugCentral

fluocinolone acetonide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: